Filing Flows › Ocular Therapeutix (OCUL) › Q2 2026 › vs Q1 2026
Ocular Therapeutix (OCUL) Q2 2026 vs Q1 2026 (quarter over quarter)
Ocular Therapeutix's revenue rose $2.7M (+25%) from $10.8M in Q1 2026 to $13.5M in Q2 2026.
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $13.5M | $10.8M | $2.7M | +25% |
| Other income, net | $3.3M | $4.7M | −$1.4M | -29% |
| Net loss | $78.8M | $88.6M | −$9.8M | -11% |
| Costs & expenses | $95.6M | $104M | −$8.5M | -8% |
| Operating costs | $95.6M | $104M | −$8.5M | -8% |
| Cost of revenue | $2.0M | $1.3M | $682K | +51% |
| Research & development | $54.1M | $66.2M | −$12.1M | -18% |
| Sales & marketing | $17.3M | $16.6M | $699K | +4% |
| General & admin | $22.2M | $20.0M | $2.2M | +11% |
| Operating cash sources | $83.8M | $82.9M | $914K | +1% |
| Depreciation & amortization | $1.9M | $1.3M | $568K | +44% |
| Share-based compensation | $14.6M | $15.6M | −$933K | -6% |
| Cash used in operations | $67.3M | $66.0M | $1.3M | +2% |
| Net loss absorbed | $78.8M | $88.6M | −$9.8M | -11% |
| Working capital & other | $5.0M | −$5.8M | $10.8M | — |
Questions
How much did Ocular Therapeutix's revenue grow quarter over quarter in Q2 2026?
Ocular Therapeutix's revenue rose $2.7M (+25%) from $10.8M in Q1 2026 to $13.5M in Q2 2026.